-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, Premier Li Keqiang presided over an executive meeting of the State Council to deploy and accelerate major projects identified in the "14th Five-Year Plan" Outline and special plans to expand effective investment; it was decided to normalize and institutionalize the development of pharmaceuticals and high-value medical consumables.
Centralized procurement with volume to further reduce the medical burden on patients
.
The meeting also pointed out that in recent years, the reform of centralized procurement of medicines and high-value medical consumables has been continuously advanced, and the market-oriented mechanism has effectively suppressed the inflated prices of medicines.
This enables pharmaceutical companies to devote more energy to product development and quality improvement
.
In the next step, it is necessary to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
The first is to focus on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out provincial or inter-provincial alliance procurement of drugs outside the national centralized procurement
.
By the end of this year, there will be more than 350 medicines in each province at the national and provincial levels
.
The second is to gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public
.
The third is to ensure the long-term stable supply of the selected drugs and consumables, strengthen supervision, and ensure that the price of the selected products does not deteriorate
.
Medical institutions should give reasonable priority to the use of the selected products
.
The fourth is to implement the policy of retaining the balance of medical insurance funds for centralized procurement, promote the reform of the salary system, reasonably increase the income of medical staff, and better mobilize their enthusiasm
.
Centralized procurement with volume to further reduce the medical burden on patients
.
The meeting also pointed out that in recent years, the reform of centralized procurement of medicines and high-value medical consumables has been continuously advanced, and the market-oriented mechanism has effectively suppressed the inflated prices of medicines.
This enables pharmaceutical companies to devote more energy to product development and quality improvement
.
In the next step, it is necessary to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
The first is to focus on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out provincial or inter-provincial alliance procurement of drugs outside the national centralized procurement
.
By the end of this year, there will be more than 350 medicines in each province at the national and provincial levels
.
The second is to gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public
.
The third is to ensure the long-term stable supply of the selected drugs and consumables, strengthen supervision, and ensure that the price of the selected products does not deteriorate
.
Medical institutions should give reasonable priority to the use of the selected products
.
The fourth is to implement the policy of retaining the balance of medical insurance funds for centralized procurement, promote the reform of the salary system, reasonably increase the income of medical staff, and better mobilize their enthusiasm
.
